Clinical Research, Pharma & Healthcare FinancingSavara Secures Up to $200M Non-Dilutive Debt FinancingBusiness WireMarch 27, 2025March 28, 2025 by Business WireMarch 27, 2025March 28, 2025037 Includes $30M at Close to Refinance Existing Debt Facility Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today...
